GlassScriptPhysician profile
Elizabeth Tyson
NPI 1750951323
$2,938.90
in general payments reported to CMS, 2019-2025
27 companies · $2,574 in 2025
The $2,574 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $240 · 2024: $125 · 2025: $2,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,938.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.25 | 2023-2025 | |
| Ucb, INC. | $267.78 | 2025 | Rystiggo, Nayzilam, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $247.92 | 2025 | Ultomiris |
| Biogen, INC. | $223.12 | 2025 | Vumerity, Leqembi, Tysabri |
| Lundbeck LLC | $157.26 | 2025 | Vyepti, Rexulti |
| Argenx US, INC. | $155.54 | 2025 | Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $154.69 | 2025 | |
| Pfizer INC. | $153.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.51 | 2025 | Hyqvia |
| Neurelis, INC. | $99.48 | 2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $81.93 | 2025 | Ajovy, Austedo Xr |
| Eisai INC. | $73.70 | 2025 | |
| Merz Pharmaceuticals, LLC | $67.87 | 2025 | Inbrija, Xeomin |
| Astrazeneca Pharmaceuticals LP | $53.35 | 2025 | Wainua |
| Tanabe Pharma America, INC. | $52.48 | 2025 | Radicava |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $50.45 | 2025 | Kisunla |
| Ani Pharmaceuticals, INC. | $41.71 | 2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $40.98 | 2025 | Ponvory |
| Amneal Pharmaceuticals LLC | $37.53 | 2025 | Crexont |
| Csl Behring | $36.62 | 2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $33.99 | 2025 | Rexulti |
| Sk Life Science, INC. | $31.90 | 2025 | |
| Janssen Biotech, INC. | $28.59 | 2025 | |
| Harmony Biosciences LLC | $24.91 | 2025 | |
| Microtransponder, INC. | $24.76 | 2025 | |
| Emd Serono, INC. | $21.31 | 2025 | |
| Genzyme Corporation | $18.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.